Recently, a median survival time of 7 months was reported for dogs receiving radiation therapy along with chemotherapy; whereas a combination of surgery and chemotherapy showed more encouraging median survival rates of 235 - 366 days with up to 28 % surviving two years after diagnosis. (wearethecure.org)
In fact, ipilimumab proved to be the first medication to significantly expand median survival rates in patients with advanced melanoma — from six months to 11. (discovermagazine.com)
In the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated. (invivoscribe.com)